76 related articles for article (PubMed ID: 20123124)
1. A novel germline mutation in peroxisome proliferator-activated receptor gamma gene associated with large intestine polyp formation and dyslipidemia.
Capaccio D; Ciccodicola A; Sabatino L; Casamassimi A; Pancione M; Fucci A; Febbraro A; Merlino A; Graziano G; Colantuoni V
Biochim Biophys Acta; 2010 Jun; 1802(6):572-81. PubMed ID: 20123124
[TBL] [Abstract][Full Text] [Related]
2. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
Lüdtke A; Buettner J; Schmidt HH; Worman HJ
J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
[TBL] [Abstract][Full Text] [Related]
3. Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy.
Jeninga EH; van Beekum O; van Dijk AD; Hamers N; Hendriks-Stegeman BI; Bonvin AM; Berger R; Kalkhoven E
Mol Endocrinol; 2007 May; 21(5):1049-65. PubMed ID: 17312272
[TBL] [Abstract][Full Text] [Related]
4. Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3.
Miehle K; Porrmann J; Mitter D; Stumvoll M; Glaser C; Fasshauer M; Hoffmann K
Clin Endocrinol (Oxf); 2016 Jan; 84(1):141-8. PubMed ID: 26119484
[TBL] [Abstract][Full Text] [Related]
5. Adipocyte-type fatty acid-binding protein as inter-compartmental shuttle for peroxisome proliferator activated receptor gamma agonists in cultured cell.
Adida A; Spener F
Biochim Biophys Acta; 2006 Feb; 1761(2):172-81. PubMed ID: 16574478
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
[TBL] [Abstract][Full Text] [Related]
7. Structural Insights into the Loss-of-Function R288H Mutant of Human PPARγ.
Egawa D; Ogiso T; Nishikata K; Yamamoto K; Itoh T
Biol Pharm Bull; 2021; 44(9):1196-1201. PubMed ID: 34471047
[TBL] [Abstract][Full Text] [Related]
8. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy.
Hegele RA; Cao H; Frankowski C; Mathews ST; Leff T
Diabetes; 2002 Dec; 51(12):3586-90. PubMed ID: 12453919
[TBL] [Abstract][Full Text] [Related]
9. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
[TBL] [Abstract][Full Text] [Related]
10. The intestinal bioavailability of vaccenic acid and activation of peroxisome proliferator-activated receptor-α and -γ in a rodent model of dyslipidemia and the metabolic syndrome.
Wang Y; Jacome-Sosa MM; Ruth MR; Lu Y; Shen J; Reaney MJ; Scott SL; Dugan ME; Anderson HD; Field CJ; Proctor SD; Vine DF
Mol Nutr Food Res; 2012 Aug; 56(8):1234-46. PubMed ID: 22714958
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
[TBL] [Abstract][Full Text] [Related]
12. The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis.
Hummasti S; Tontonoz P
Mol Endocrinol; 2006 Jun; 20(6):1261-75. PubMed ID: 16556736
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor gamma-ligand-binding domain mutations associated with familial partial lipodystrophy type 3 disrupt human trophoblast fusion and fibroblast migration.
Shoaito H; Chauveau S; Gosseaume C; Bourguet W; Vigouroux C; Vatier C; Pienkowski C; Fournier T; Degrelle SA
J Cell Mol Med; 2020 Jul; 24(13):7660-7669. PubMed ID: 32519441
[TBL] [Abstract][Full Text] [Related]
14. APC mutation spectrum in ileoanal pouch polyps resembles that of colorectal polyps.
Will OC; Robinson J; Günther T; Phillips RK; Clark SK; Tomlinson I
Br J Surg; 2008 Jun; 95(6):765-9. PubMed ID: 18418860
[TBL] [Abstract][Full Text] [Related]
15. The role of the amino-terminal domain in the interaction of unliganded peroxisome proliferator-activated receptor gamma-2 with nuclear receptor co-repressor.
Suzuki S; Sasaki S; Morita H; Oki Y; Turiya D; Ito T; Misawa H; Ishizuka K; Nakamura H
J Mol Endocrinol; 2010 Sep; 45(3):133-45. PubMed ID: 20587609
[TBL] [Abstract][Full Text] [Related]
16. A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators.
Vottero A; Kino T; Combe H; Lecomte P; Chrousos GP
J Clin Endocrinol Metab; 2002 Jun; 87(6):2658-67. PubMed ID: 12050230
[TBL] [Abstract][Full Text] [Related]
17. A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy.
Al-Shali K; Cao H; Knoers N; Hermus AR; Tack CJ; Hegele RA
J Clin Endocrinol Metab; 2004 Nov; 89(11):5655-60. PubMed ID: 15531525
[TBL] [Abstract][Full Text] [Related]
18. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation.
Bouaboula M; Hilairet S; Marchand J; Fajas L; Le Fur G; Casellas P
Eur J Pharmacol; 2005 Jul; 517(3):174-81. PubMed ID: 15987634
[TBL] [Abstract][Full Text] [Related]
19. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
Puhl AC; Bernardes A; Silveira RL; Yuan J; Campos JL; Saidemberg DM; Palma MS; Cvoro A; Ayers SD; Webb P; Reinach PS; Skaf MS; Polikarpov I
Mol Pharmacol; 2012 Jun; 81(6):788-99. PubMed ID: 22391103
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice.
Yang K; Fan KH; Lamprecht SA; Edelmann W; Kopelovich L; Kucherlapati R; Lipkin M
Int J Cancer; 2005 Sep; 116(4):495-9. PubMed ID: 15818612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
